Bioheart Inc. (BHRT) 0.0056 $BHRT
Bioheart Highlights Positive First Quarter Results
ACCESSWIRE - Wed May 06, 7:02AM CDT
SUNRISE, FL / ACCESSWIRE / May 6, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT) highlights today the positive results from its first quarter 2015 operations:
Kristin Comella, CSO Blogs with Paul Knoepfler on Bioheart and US Stem Cell Clinic and Training
ACCESSWIRE - Wed Apr 22, 8:02AM CDT
SUNRISE, FL / ACCESSWIRE / April 22, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB) announces today that Kristin Comella's blog interview with Paul Knoepfler, the Knoepfler Lab Stem Cell Blog is available on line through the following link:
Bioheart Posts Contact Information for its Upcoming Conference Call
ACCESSWIRE - Mon Apr 20, 11:17AM CDT
SUNRISE, FL / ACCESSWIRE / APRIL 20, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today the following contact information for its 1st Quarter Preview Conference Call to be held on Thursday, April 23rd at 4:30 EDT. Participants can join the call through the Company's GoToMeeting portal or by phone using the following links:
US Stem Cell Clinic Increases Staff to Support Patient Demand and Marketing
ACCESSWIRE - Thu Apr 16, 11:01AM CDT
SUNRISE, FL / ACCESSWIRE / April 16, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that its US Stem Cell Clinic division has increased its staff to support increasing patient demand and the creation and launch of new marketing initiatives.
Bioheart to Preview Positive 1st Quarter Results in Upcoming Conference Call
ACCESSWIRE - Wed Apr 15, 11:20AM CDT
SUNRISE, FL / ACCESSWIRE / April 15, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that it will hold a 1st Quarter Review Conference Call on Thursday, April 23rd, 2015 at 4:30 PM EDT. The call will highlight research and development, business and corporate accomplishments for the first quarter of 2015 and goals for the second quarter. Webinar and dial-in numbers for the conference call will be posted on Monday, April 20, 2015.
Sell Great Basin Scientific Inc., Penny Stock Newsletter Pumps Don't End Well
Big Banks - at Seeking Alpha - Mon Apr 06, 2:31PM CDT
GNMK: 9.40 (-0.02), GBSN: 3.29 (+0.07), RCAP: 7.83 (-0.13), QDEL: 23.05 (+0.03), CPHD: 57.71 (-0.39), RTGN: 4.04 (+0.02)
Bioheart and Ascyrus Medical Execute Investment Agreement
ACCESSWIRE - Thu Mar 19, 8:31AM CDT
SUNRISE, FL / ACCESSWIRE / March 19, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT) and Ascyrus Medical, LLC, a Florida Limited Liability Corporation are pleased to announce that they have entered into an investment agreement. The investment agreement provides for Bioheart to obtain a consolidating ownership stake in Ascyrus Medical upon the achievement of certain business milestones. Bioheart has through June 30, 2015 to meet its milestone obligations.
Bioheart Touts 2014 Accomplishments; Seeks More in 2015
ACCESSWIRE - Tue Mar 17, 1:27PM CDT
SUNRISE, FL / ACCESSWIRE / March 17, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
Bioheart Strengthens Management Team with Appointment of Martin E. Schmieg as President of Vetbiologics, Inc.
ACCESSWIRE - Wed Feb 11, 10:18AM CST
SUNRISE, FL / ACCESSWIRE / February 11, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today the appointment of Martin E. Schmieg as President of Vetbiologics, Inc., the Company's wholly owned animal health subsidiary.
Bioheart Updates and Diversifies Its Clinical Development Pipeline
ACCESSWIRE - Thu Jan 29, 9:00AM CST
SUNRISE, FL / ACCESSWIRE / January 29, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today an update and diversification plan for its clinical development pipeline. The company's update includes a realignment of its cardiovascular product candidates and diversification into the treatment of autoimmune diseases with a first generation, investigational research program to treat Rheumatoid Arthritis (RA).
Bioheart Confirms Date and Access for Shareholder Conference Call
ACCESSWIRE - Wed Jan 28, 9:00AM CST
Strategic Direction for 2015 and Forward to be Highlighted
Bioheart to repurchase shares
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 11:38AM CST
Bioheart Announces Date for Shareholder Conference Call
ACCESSWIRE - Wed Jan 14, 9:00AM CST
Strategic Direction for 2015 and Forward to be Highlighted
Bioheart Board of Directors Authorizes a Repurchase of the Company's Outstanding Common Stock
ACCESSWIRE - Tue Jan 13, 9:01AM CST
SUNRISE, FL / ACCESSWIRE / January 13, 2015 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies a Florida corporation, today announced that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase outstanding Common Stock when beneficially prudent for the Company and its shareholders.
Bioheart Announces Completion of First Stem Cell Training in Australia
ACCESSWIRE - Mon Dec 22, 9:09AM CST
SUNRISE, FL / ACCESSWIRE / December 22, 2014 / Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces completion of the first stem cell training course to bring regenerative therapies to Australia. (www.usstemcelltraining.com)
Bioheart Announces Joint Venture In Nigeria
ACCESSWIRE - Thu Dec 18, 7:01AM CST
SUNRISE, FL / ACCESSWIRE / December 18, 2014 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Prosper Igboeli of Nigeria.
Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
ACCESSWIRE - Mon Nov 17, 7:01AM CST
Untitled Document
Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan
ACCESSWIRE - Wed Nov 12, 10:22AM CST
SUNRISE, FL / ACCESSWIRE / November 12, 2014 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today that the first successful intracoronary implantation of autologous adipose-derived stem cell (ADSC) was performed to a 70 year-old male patient with ischemic cardiomyopathy by Emrah Anar MD (Chief of Cardiology and Cardiovascular Surgery) in Baku (Azerbaijan) Cardiac Center of Central Military Hospital.
Miami Dade College Names Bioheart CEO, Mike Tomas, to Board of Advisors for New Idea Center
Marketwired - Thu Oct 30, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomas, President and CEO, will sit on the board of advisors for Miami Dade College's new Idea Center which will serve as Miami Dade College's hub for entrepreneurship for its 165,000 students. The Idea Center will include a venture incubator, called CREATE, with programming and resources to help nurture and accelerate the entrepreneurial ideas and ventures of students.
Bioheart, Inc. Completes Financing With Magna
Marketwired - Fri Oct 24, 3:00PM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, a Florida corporation, is pleased to announce the closing of a common stock purchase agreement for a $3 million Equity Enhancement Program ("EEP"
with a Magna affiliate fund, Magna Equities II, LLC (the "Investor". The EEP allows, but does not obligate the Company to issue and sell up to $3,000,000 worth of the Company's common stock to the Investor from time to time, over the 24-month term of the purchase agreement.
Bioheart Highlights Positive First Quarter Results
ACCESSWIRE - Wed May 06, 7:02AM CDT
SUNRISE, FL / ACCESSWIRE / May 6, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT) highlights today the positive results from its first quarter 2015 operations:
Kristin Comella, CSO Blogs with Paul Knoepfler on Bioheart and US Stem Cell Clinic and Training
ACCESSWIRE - Wed Apr 22, 8:02AM CDT
SUNRISE, FL / ACCESSWIRE / April 22, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB) announces today that Kristin Comella's blog interview with Paul Knoepfler, the Knoepfler Lab Stem Cell Blog is available on line through the following link:
Bioheart Posts Contact Information for its Upcoming Conference Call
ACCESSWIRE - Mon Apr 20, 11:17AM CDT
SUNRISE, FL / ACCESSWIRE / APRIL 20, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today the following contact information for its 1st Quarter Preview Conference Call to be held on Thursday, April 23rd at 4:30 EDT. Participants can join the call through the Company's GoToMeeting portal or by phone using the following links:
US Stem Cell Clinic Increases Staff to Support Patient Demand and Marketing
ACCESSWIRE - Thu Apr 16, 11:01AM CDT
SUNRISE, FL / ACCESSWIRE / April 16, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that its US Stem Cell Clinic division has increased its staff to support increasing patient demand and the creation and launch of new marketing initiatives.
Bioheart to Preview Positive 1st Quarter Results in Upcoming Conference Call
ACCESSWIRE - Wed Apr 15, 11:20AM CDT
SUNRISE, FL / ACCESSWIRE / April 15, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that it will hold a 1st Quarter Review Conference Call on Thursday, April 23rd, 2015 at 4:30 PM EDT. The call will highlight research and development, business and corporate accomplishments for the first quarter of 2015 and goals for the second quarter. Webinar and dial-in numbers for the conference call will be posted on Monday, April 20, 2015.
Sell Great Basin Scientific Inc., Penny Stock Newsletter Pumps Don't End Well
Big Banks - at Seeking Alpha - Mon Apr 06, 2:31PM CDT
GNMK: 9.40 (-0.02), GBSN: 3.29 (+0.07), RCAP: 7.83 (-0.13), QDEL: 23.05 (+0.03), CPHD: 57.71 (-0.39), RTGN: 4.04 (+0.02)
Bioheart and Ascyrus Medical Execute Investment Agreement
ACCESSWIRE - Thu Mar 19, 8:31AM CDT
SUNRISE, FL / ACCESSWIRE / March 19, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT) and Ascyrus Medical, LLC, a Florida Limited Liability Corporation are pleased to announce that they have entered into an investment agreement. The investment agreement provides for Bioheart to obtain a consolidating ownership stake in Ascyrus Medical upon the achievement of certain business milestones. Bioheart has through June 30, 2015 to meet its milestone obligations.
Bioheart Touts 2014 Accomplishments; Seeks More in 2015
ACCESSWIRE - Tue Mar 17, 1:27PM CDT
SUNRISE, FL / ACCESSWIRE / March 17, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
Bioheart Strengthens Management Team with Appointment of Martin E. Schmieg as President of Vetbiologics, Inc.
ACCESSWIRE - Wed Feb 11, 10:18AM CST
SUNRISE, FL / ACCESSWIRE / February 11, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today the appointment of Martin E. Schmieg as President of Vetbiologics, Inc., the Company's wholly owned animal health subsidiary.
Bioheart Updates and Diversifies Its Clinical Development Pipeline
ACCESSWIRE - Thu Jan 29, 9:00AM CST
SUNRISE, FL / ACCESSWIRE / January 29, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today an update and diversification plan for its clinical development pipeline. The company's update includes a realignment of its cardiovascular product candidates and diversification into the treatment of autoimmune diseases with a first generation, investigational research program to treat Rheumatoid Arthritis (RA).
Bioheart Confirms Date and Access for Shareholder Conference Call
ACCESSWIRE - Wed Jan 28, 9:00AM CST
Strategic Direction for 2015 and Forward to be Highlighted
Bioheart to repurchase shares
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 11:38AM CST
Bioheart Announces Date for Shareholder Conference Call
ACCESSWIRE - Wed Jan 14, 9:00AM CST
Strategic Direction for 2015 and Forward to be Highlighted
Bioheart Board of Directors Authorizes a Repurchase of the Company's Outstanding Common Stock
ACCESSWIRE - Tue Jan 13, 9:01AM CST
SUNRISE, FL / ACCESSWIRE / January 13, 2015 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies a Florida corporation, today announced that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase outstanding Common Stock when beneficially prudent for the Company and its shareholders.
Bioheart Announces Completion of First Stem Cell Training in Australia
ACCESSWIRE - Mon Dec 22, 9:09AM CST
SUNRISE, FL / ACCESSWIRE / December 22, 2014 / Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces completion of the first stem cell training course to bring regenerative therapies to Australia. (www.usstemcelltraining.com)
Bioheart Announces Joint Venture In Nigeria
ACCESSWIRE - Thu Dec 18, 7:01AM CST
SUNRISE, FL / ACCESSWIRE / December 18, 2014 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Prosper Igboeli of Nigeria.
Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
ACCESSWIRE - Mon Nov 17, 7:01AM CST
Untitled Document
Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan
ACCESSWIRE - Wed Nov 12, 10:22AM CST
SUNRISE, FL / ACCESSWIRE / November 12, 2014 / Bioheart, Inc. (OTCQB:BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today that the first successful intracoronary implantation of autologous adipose-derived stem cell (ADSC) was performed to a 70 year-old male patient with ischemic cardiomyopathy by Emrah Anar MD (Chief of Cardiology and Cardiovascular Surgery) in Baku (Azerbaijan) Cardiac Center of Central Military Hospital.
Miami Dade College Names Bioheart CEO, Mike Tomas, to Board of Advisors for New Idea Center
Marketwired - Thu Oct 30, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomas, President and CEO, will sit on the board of advisors for Miami Dade College's new Idea Center which will serve as Miami Dade College's hub for entrepreneurship for its 165,000 students. The Idea Center will include a venture incubator, called CREATE, with programming and resources to help nurture and accelerate the entrepreneurial ideas and ventures of students.
Bioheart, Inc. Completes Financing With Magna
Marketwired - Fri Oct 24, 3:00PM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, a Florida corporation, is pleased to announce the closing of a common stock purchase agreement for a $3 million Equity Enhancement Program ("EEP"
with a Magna affiliate fund, Magna Equities II, LLC (the "Investor". The EEP allows, but does not obligate the Company to issue and sell up to $3,000,000 worth of the Company's common stock to the Investor from time to time, over the 24-month term of the purchase agreement. 
